Every intervention Outliyr has scored for bone and joint health, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for bone and joint health; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
52 of 101 evaluated interventions score 3.0+ out of 10 for bone and joint health · 13 comparisons
Vitamin D3 + K2 bone joint earns 8.0/10 because Knapen 2013 anchors the most relevant signal. Vitamin D3 + K2 fits bone joint when deficiency, bone risk, immune seasonality, or fat-soluble nutrient…
Read the Vitamin D3 + K2 report →PEMF (Pulsed Electromagnetic Field Therapy) earns 8.0/10 for bone joint; this is a targeted fit score. FDA-cleared nonunion healing 73-89% and OA pain evidence support PEMF's strongest use case. The corrected knee…
Read the PEMF (Pulsed Electromagnetic Field Therapy) report →Whole-Body Vibration scores 7.5/10 for the bone-joint use case, based on modest but measurable bone-density gains reported in postmenopausal women Li 2024. Whole-Body Vibration appears to support bone health primarily in populations…
Read the Whole-Body Vibration report →Ca-AKG (Calcium Alpha-Ketoglutarate)'s 7.4/10 bone-joint score starts with Filip 2007, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: this verified source found lower CTX bone-resorption…
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →Bone-joint scores 7.2/10 because Fan 2024 found knee osteoarthritis pain reduction across low-level laser therapy trials. The strongest target is joint pain and local inflammation, not bone density. Red Light Therapy may…
Read the Red Light Therapy report →Magnesium bone joint earns 7.0/10 because de Baaij 2015 anchors the most relevant signal. Magnesium fits bone joint when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction…
Read the Magnesium report →Glycine bone joint earns 7.0/10 because Soh 2024 anchors the most relevant signal. Glycine fits bone joint because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the…
Read the Glycine report →TRT (Testosterone Replacement Therapy) is a 7.0/10 bone and joint support fit because Lincoff 2023 reports TRAVERSE cardiovascular outcomes trial in 5,246 hypogonadal men with cardiovascular risk; major cardiovascular events non-inferior, with…
Read the TRT (Testosterone Replacement Therapy) report →Osteoarthritis is curcumin's single best-supported use. A 2022 meta-analysis by Feng and colleagues in BMC Complementary Medicine and Therapies found curcuminoids reduced WOMAC total scores (mean difference around 7 points) and were…
Read the Curcumin report →The bone and joint support case for Essential Amino Acids is 6.5/10 because Hagiyama 2024 reports 12 RCTs; 622 patients; low-certainty improvement in patient-reported outcomes and very-low-certainty strength signal after lower-limb surgeries.…
Read the Essential Amino Acids report →Shilajit bone joint earns 6.5/10 because Pingali 2022 anchors the most relevant signal. Shilajit fits bone joint when purified resin is matched to hormones, sperm parameters, strength fatigue, bone markers, or energy…
Read the Shilajit report →A 6.5/10 bone joint rating fits Senolytics, since Hickson et al. 2019 points to a real but bounded effect. Bone rationale is strong preclinically, but Farr 2024 found D+Q did not improve…
Read the Senolytics report →Population fit explains the 6.5/10 bone joint score for Celebrex (Celecoxib) because the evidence points to a plausible use case without proving a universal response. Seidenberg AB, An YH 2004 is the…
Read the Celebrex (Celecoxib) report →Refractory osteomyelitis, osteoradionecrosis, and avascular necrosis are recognized indications per UHMS 2025. This makes bone-joint one of the better medical-adjacent slugs for HBOT scoring. Score higher because the framing is clinician-supervised disease…
Read the Hyperbaric Oxygen Therapy report →In bone joint, TB-500 (Thymosin Beta-4 Fragment) earns 6.2/10 only under the right assumptions. Bone-joint use is mostly a community and mechanism extrapolation. Tbeta4 supports cell migration and inflammatory resolution, but no…
Read the TB-500 (Thymosin Beta-4 Fragment) report →Collagen Peptides earns 6.0/10 for bone joint; this is a targeted fit score. Strongest non-skin evidence. Schulze 2024 reported less lower-extremity joint discomfort with 5 g/day specific peptides, Koenig 2018 supports bone…
Read the Collagen Peptides report →Bone and joint support scores 6.0, a deliberately measured number. Mechanical loading is the right stimulus, and a 5-year weighted-vest plus jumping program preserved hip bone density in postmenopausal women while controls…
Read the Rucking (Weighted Walking) report →For bone joint, Omega-3 earns 6.0/10 because the evidence points to a plausible use case without proving a universal response. Abuknesha et al. 2025 is the best anchor here because it reports…
Read the Omega-3 report →The practical bone and joint support read on Creatine Monohydrate is 5.6/10 because Kreider 2017 reports Foundational 87-citation position stand; safe up to 30 g/day for 5 years. Lanhers 2015 points in…
Read the Creatine Monohydrate report →BPC-157 bone joint earns 5.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits bone joint when the target is tissue repair, vascular recruitment, or inflammation control, but the case still…
Read the BPC-157 report →Joint health rates 5.5/10. de Carvalho 2024 reviewed 11 studies (mostly knee osteoarthritis RCTs) and found 9 of 11 showed pain or function improvement, and Cicero 2020 showed 200 mg/day of oral…
Read the Hyaluronic Acid report →Evidence for Taurine in bone and joint support lands at 5.3/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess.…
Read the Taurine report →Zone 2 Cardio earns 5.0/10 for bone-joint because Lang 2024 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: The bone and joint score depends…
Read the Zone 2 Cardio report →A cautious bone joint score of 5.0/10 fits Blood-Flow Restriction Training, with Hughes et al. 2019 preventing a stronger claim. Wang 2023 reviewed BFR effects on bone metabolism, but bone outcomes remain…
Read the Blood-Flow Restriction Training report →Joint health scores 5.0/10. Pooled studies in Hussain 2018 reported symptom relief in rheumatic and arthritic disease, and heat is a familiar way to ease morning stiffness and improve the comfort of…
Read the Traditional Sauna (Finnish Dry-Heat) report →PEARL suggested small bone or pain signals in subgroups, but primary benefit is not established and wound-healing concerns matter.
Read the Rapamycin report →Bone and joint health scores 4.5/10. Vitamin C is required for the collagen matrix that underlies both bone and cartilage, and deficiency causes bone pain, impaired bone formation, and joint hemorrhage. Observational…
Read the Vitamin C (Ascorbic Acid) report →Bone support is inferred from androgen biology and male-osteoporosis reviews, not dedicated human bone-outcome trials. This is not a joint-pain intervention.
Read the Tongkat Ali report →Guo 2025 associated metformin with lower knee-arthroplasty incidence and lower knee-pain scores in knee osteoarthritis studies, but the authors cautioned that RCT evidence is sparse. This is exploratory, not a primary metformin…
Read the Metformin report →Running sprints add high-rate ground-reaction loading that can support bone, but they also raise tendon and joint injury risk; cycle and rower SIT add little skeletal loading.
Read the Sprinting (Sprint Interval Training) report →Bone-joint support is hypothesis-generating, not a primary indication. Thaung Zaw 2020 included postmenopausal women and provides the adjacent vascular/cognitive population context, but resveratrol lacks a dedicated, replicated osteoporosis or osteoarthritis RCT program.…
Read the Resveratrol report →Weight loss reduces mechanical knee load, and Lilly's TRIUMPH-4 topline reported WOMAC pain improvements in obesity with knee osteoarthritis. Full peer-reviewed data are still pending, so the v0.x score remains held.
Read the Retatrutide report →Bone and joint is one of the better-supported uses, though the proof is thinner than the bladder data. A placebo-controlled knee pilot of 114 people found that into-muscle pentosan improved stiffness and…
Read the Pentosan Polysulfate (Elmiron) report →Farr 2024 phase 2 intermittent D plus Q in 60 postmenopausal women was null on the primary bone turnover endpoint overall. An exploratory high p16 tertile showed P1NP up 34 percent, CTx…
Read the Quercetin report →Treadmill and uphill running add impact and loading, but the protocol is not a bone-density plan. Bike-based 4x4 has little direct skeletal loading.
Read the Norwegian 4×4 report →Anti-inflammatory mechanism may support joint comfort, but direct joint-specific human RCT evidence remains sparse.
Read the Astaxanthin report →Bone and joint scores 4.0/10. Anti-inflammatory mechanism and some isoflavone bone-density signals exist, but direct joint-outcome evidence for the dietary class is sparse.
Read the Polyphenols (Dietary) report →Bone-joint remains speculative relative to skin. GHK-Cu supports collagen and tissue repair biology, and Pickart reviews mention bone repair in preclinical contexts, but clinical osteoarthritis, fracture, or joint-pain trials are not established.…
Read the GHK-Cu report →WB-EMS creates muscular loading with lower external joint load, which helps users who cannot tolerate heavy lifting. Direct bone-density evidence is weaker than conventional resistance training, so this is supportive but not…
Read the Full-Body EMS report →Bone-joint support is anti-inflammatory and trial-limited. V0 preserved an osteoarthritis-like KSM-66 signal, but the audit did not re-verify all joint-specific details. Score remains moderate because the mechanism fits but the evidence is…
Read the Ashwagandha report →Two osteoarthritis trials used seaweed-blend or fucoidan products with mixed symptom benefit and no consistent marker change.
Read the Fucoidan (Brown Seaweed Polysaccharide) report →Bone concerns concentrate in pediatric classical keto and long-term strict use. Clinical epilepsy protocols monitor calcium, vitamin D, growth, and bone density because risk is real. Adult short-term keto usually does not…
Read the Ketogenic Diet report →Ming 2016 showed MOTS-c suppressed ovariectomy-induced bone loss through AMPK activation in mice, supporting a preclinical bone signal. The score stays 3.5 because no human osteoporosis, joint, or fracture trial exists.
Read the MOTS-c report →GH/IGF-1 signaling supports bone remodeling, but tesamorelin trials did not establish DEXA bone-density improvement or joint-specific benefit. Arthralgia is also a known tolerability issue.
Read the Tesamorelin report →Mechanical joint relief is real in obesity, but rapid weight loss can reduce bone density and lean-mass support if poorly managed.
Read the Semaglutide report →Bone support rests on one animal study: Polak 2025 found pine pollen at 150 mg/kg limited cortical and trabecular bone loss in orchidectomized rats. Promising but single-study and animal-only; no human bone…
Read the Pine Pollen report →C60 bone-joint scoring stays at 3.5 because no clinical trial has tested C60 against joint pain, cartilage, osteoarthritis, fracture healing, or bone-density endpoints. Anecdotal joint reports are scattered and selection-biased. The antioxidant…
Read the C60 (Buckminsterfullerene) report →Magnesium supports bone mineral physiology and potassium may reduce urinary calcium loss, but the evidence is indirect.
Read the Electrolytes report →No meaningful human bone or joint outcome evidence; anti-inflammatory mechanism only.
Read the Ergothioneine report →Joint load may improve with weight loss, but v0.x bone-loss and fracture concerns remain part of the downside rationale; no audit-verified protective bone trial was supplied.
Read the Tirzepatide report →Calcium and magnesium contribute to bone biology generally, but no bone or joint endpoint trial used marine plasma.
Read the Quinton Marine Plasma (Seawater Minerals) report →Exercise benefits bone and joints through mechanical loading, but SLU-PP-332 does not replicate loading. No bone-density, cartilage, arthritis, or joint-pain data exists for the compound, so this remains mostly theoretical.
Read the SLU-PP-332 report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
Shilajit at 7.4, phosphatidylserine at 7.3, tongkat ali at 7.0. TRT ranks seventh at 5.7 and wins nine of the eleven use cases outright. That inversion is the…
Neither, if fat loss is the goal. Both score 2.0 on body composition, which is the row a vendor sells them on. AOD-9604 scores 4.6 overall and its…
These two get sold as the same thing, a scoop for gut and skin, and they share almost no mechanism. Colostrum is a gut and immune product: gut…
Different jobs, same shelf. Quercetin scores 6.8 and curcumin 6.5, which decides nothing. Curcumin wins joints, inflammatory markers, gut and mood. Quercetin wins allergies, blood pressure, uric acid…
Magnesium glycinate is magnesium bound to glycine, so if you take it you already take both. That kills the question for sleep. The real decision: magnesium scores higher…
Buy the panel. Red light therapy scores 8.0 against HBOT's 6.2, costs $17 to $43 a month against $3,000 to $6,000, and does not lose a single use…
Kisspeptin-10 scores 6.4 and TRT 5.7, and TRT still wins 13 of the 15 use cases both reports score. The higher number reflects dependency and reversibility, not effect.…
Red light therapy scores 8.0 and PEMF 7.5, so the panel is the better first buy for most people. PEMF wins on bone and joint pain, where a…
Start on sermorelin. Ipamorelin scores higher overall, yet sermorelin wins thirteen of the sixteen shared use cases and it is the one an anti-aging clinic actually prescribes. Ipamorelin…
Shilajit scores 7.4 and ashwagandha 6.8, but that gap is the least useful number here. These two do different jobs. Shilajit is the mineral and androgen play: male…
Start tirzepatide. It scores 6.1 against retatrutide's 5.6, and the gap is mostly availability and evidence maturity rather than weaker biology. Retatrutide is not approved anywhere, cannot legally…
Both score 6.2, and that tie hides the real picture. Tesamorelin outscores ipamorelin on all 16 shared use cases and carries Phase 3 trials on visceral and liver…
Vitamin D3 + K2, at 8.0 out of 10 for bone and joint health. Vitamin D3 + K2 bone joint earns 8.0/10 because Knapen 2013 anchors the most relevant signal.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 7.0 out of 10 for bone and joint health.
52 of the 101 interventions evaluated for bone and joint health score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
